



# Stabilis



## Dapsone



### Stabilité des préparations

|  |  | 300 mg ® = ?                        | SyrSpend SF® PH4 >> 150 mL                                              | 2-8°C   |  | 90 |  |  | 3819 |
|--|--|-------------------------------------|-------------------------------------------------------------------------|---------|--|----|--|--|------|
|  |  | 300 mg ® = ?                        | SyrSpend SF® PH4 >> 150 mL                                              | 20-25°C |  | 90 |  |  | 3819 |
|  |  | 60 mg ® = Jacobus Pharmaceutical    | Oral Mix SF® >> 30 mL                                                   | 23-27°C |  | 90 |  |  | 4106 |
|  |  | 60 mg ® = Jacobus Pharmaceutical    | Oral Mix® >> 30 mL                                                      | 23-27°C |  | 90 |  |  | 4106 |
|  |  | 400 mg ®=? (Jacobus Pharmaceutical) | OraPlus® / OraSweet® (1:1) >> 200 mL                                    | 2-8°C   |  | 90 |  |  | 2545 |
|  |  | 400 mg ®=? (Jacobus Pharmaceutical) | Acide citrique 1000 mg<br>Eau distillée 50 ml<br>Sirop simple >> 200 ml | 25°C    |  | 90 |  |  | 2545 |
|  |  | 60 mg ® = Jacobus Pharmaceutical    | Oral Mix SF® >> 30 mL                                                   | 3-7°C   |  | 90 |  |  | 4106 |
|  |  | 60 mg ® = Jacobus Pharmaceutical    | Oral Mix® >> 30 mL                                                      | 3-7°C   |  | 90 |  |  | 4106 |
|  |  | 400 mg ®=? (Jacobus Pharmaceutical) | OraPlus® / OraSweet® (1:1) >> 200 mL                                    | 2-8°C   |  | 90 |  |  | 2545 |
|  |  | 400 mg ®=? (Jacobus Pharmaceutical) | Acide citrique 1000 mg<br>Eau distillée 50 ml<br>Sirop simple >> 200 ml | 4°C     |  | 90 |  |  | 2545 |
|  |  | 2 mg ® = Jacobus Pharmaceutical     | Oral Mix SF® >> 1 mL                                                    | 23-27°C |  | 90 |  |  | 4106 |
|  |  | 2 mg ® = Jacobus Pharmaceutical     | Oral Mix® >> 1 mL                                                       | 23-27°C |  | 90 |  |  | 4106 |
|  |  | 2 mg ® = Jacobus Pharmaceutical     | Oral Mix SF® >> 1 mL                                                    | 3-7°C   |  | 90 |  |  | 4106 |
|  |  | 2 mg ® = Jacobus Pharmaceutical     | Oral Mix® >> 1 mL                                                       | 3-7°C   |  | 90 |  |  | 4106 |






















## Bibliographie

|      | Type  | Source                                                                                                                                                                                                                                                                                                                                                                |
|------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2545 | Revue | Nahata MC, Morosco RC, Trowbridge JM.<br>Stability of dapsone in two oral liquid dosage forms.<br><br>Ann Pharmacotherapy 2000 ;34:848-850.                                                                                                                                                                                                                           |
| 3819 | Revue | Ferreira A.O, Polonina H.C, Silva S.L, Patricio F.B, Brand?oa M.A.F, Raposo N.R.B.<br>Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions.<br>J Pharm Biomed Anal 2015 ; 118: 105-112. |
| 4106 | Revue | Alarie H, Friciu M, Leclair G.<br>Stability of Dapsone in Extemporaneously Compounded Oral Suspensions.<br>Can J Hosp Pharm 2018 ;71,2/152-154                                                                                                                                                                                                                        |



# Dictionnaire

|                                                                                                              |                                                                                                    |
|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|  Antibiotique               |  Solution buvable |
|  Stabilité des préparations |  Contenant        |
|  Origine                    |  Excipient        |
|  Température                |  Conservation     |
|  Durée de stabilité         |  Biosimilaire     |
|  Données conflictuelles     |  Bibliographie    |
|  Flacon plastique           |  Comprimés        |
|  A l'abri de la lumière     |  Jour             |
|  Seringue PP orale          |  Bibliographie    |
|  Dictionnaire               |                                                                                                    |